Paper · 29430504

Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer.

Todenhöfer T and 4 others. Bladder Cancer, 2018. Cited by 48 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer. Papers, record 29430504. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29430504

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer.; PubMed
Journal: Bladder Cancer; PubMed
Year: 2018; PubMed
Publication types: Journal Article, Review; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/29430504/; PubMed
DOI: https://doi.org/10.3233/blc-170140; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC5798499/; PubMed
The journal: https://conductscience.org/library/journal-index/101668567; PubMed
Citations, by iCite: 48; iCite
Relative citation ratio, by iCite: 1.75; iCite
Revised in PubMed: 2020-10-01; PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Todenhöfer T	Tilman
2	Struss WJ	Werner J
3	Seiler R	Roland
4	Wyatt AW	Alexander William
5	Black PC	Peter C

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References44

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	28,814,544	Direct detection of early-stage cancers using circulating tumor DNA.	Sci Transl Med	2017	https://conductscience.org/library/papers/28814544	PubMed
2	26,952,546	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.	Lancet	2016	https://conductscience.org/library/papers/26952546	PubMed
3	24,553,385	Detection of circulating tumor DNA in early- and late-stage human malignancies.	Sci Transl Med	2014	https://conductscience.org/library/papers/24553385	PubMed
4	28,445,469	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.	Nature	2017	https://conductscience.org/library/papers/28445469	PubMed
5	21,562,580	Cell-free nucleic acids as biomarkers in cancer patients.	Nat Rev Cancer	2011	https://conductscience.org/library/papers/21562580	PubMed
6	26,771,485	Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin.	Cell	2016	https://conductscience.org/library/papers/26771485	PubMed
7	26,803,478	Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.	Eur Urol	2016	https://conductscience.org/library/papers/26803478	PubMed
8	28,717,136	Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer.	Sci Rep	2017	https://conductscience.org/library/papers/28717136	PubMed
9	26,969,689	Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.	Cancer Discov	2016	https://conductscience.org/library/papers/26969689	PubMed
10	28,988,769	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.	Cell	2017	https://conductscience.org/library/papers/28988769	PubMed

1 to 10 of 44

See all 44 references

Cited by26

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 48 citations.

PMID	Title	Journal	Year	In Papers	Source
42,038,393	Circulating tumor DNA as a prognostic and monitoring biomarker in urothelial cancers.	Front Oncol	2026	https://conductscience.org/library/papers/42038393	PubMed
41,971,128	Predicting inguinal lymph node metastasis in penile squamous cell carcinoma, from imaging, molecular biomarkers to multimodal AI: a narrative review.	Transl Androl Urol	2026	https://conductscience.org/library/papers/41971128	PubMed
40,698,358	Liquid Biopsy: Current advancements in clinical practice for bladder cancer.	J Liq Biopsy	2025	https://conductscience.org/library/papers/40698358	PubMed
40,364,842	Prognostic significance of circulating tumor DNA in urothelial carcinoma patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.	Front Immunol	2025	https://conductscience.org/library/papers/40364842	PubMed
40,274,976	Monitoring circulating tumor DNA by recurrent hotspot mutations in bladder cancer.	BJC Rep	2025	https://conductscience.org/library/papers/40274976	PubMed
40,191,434	Circulating tumor DNA: a revolutionary approach for early detection and personalized treatment of bladder cancer.	Front Pharmacol	2025	https://conductscience.org/library/papers/40191434	PubMed
39,473,210	Circulating Tumor Cells in Cancer Diagnosis, Therapy, and Theranostics Applications: An Overview of Emerging Materials and Technologies.	Curr Pharm Des	2025	https://conductscience.org/library/papers/39473210	PubMed
38,387,284	Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness.	Drug Resist Updat	2024	https://conductscience.org/library/papers/38387284	PubMed
38,071,680	An Investigation into Cell-Free DNA in Different Common Cancers.	Mol Biotechnol	2024	https://conductscience.org/library/papers/38071680	PubMed
37,358,142	Examining longitudinal markers of bladder cancer recurrence through a semiautonomous machine learning system for quantifying specimen atypia from urine cytology.	Cancer Cytopathol	2023	https://conductscience.org/library/papers/37358142	PubMed

1 to 10 of 26

See all 26 cited by

Genes23

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
ADD1	118	PubTator's text mining	https://conductscience.org/library/genes/118	NCBI Gene
AR	367	PubTator's text mining	https://conductscience.org/library/genes/367	NCBI Gene
ARID1A	8,289	PubTator's text mining	https://conductscience.org/library/genes/8289	NCBI Gene
BRAF	673	PubTator's text mining	https://conductscience.org/library/genes/673	NCBI Gene
CD274	29,126	PubTator's text mining	https://conductscience.org/library/genes/29126	NCBI Gene
CDKN2A	1,029	PubTator's text mining	https://conductscience.org/library/genes/1029	NCBI Gene
CTNNB1	1,499	PubTator's text mining	https://conductscience.org/library/genes/1499	NCBI Gene
ERBB2	2,064	PubTator's text mining	https://conductscience.org/library/genes/2064	NCBI Gene
ERCC2	2,068	PubTator's text mining	https://conductscience.org/library/genes/2068	NCBI Gene
FGFR3	2,261	PubTator's text mining	https://conductscience.org/library/genes/2261	NCBI Gene

1 to 10 of 23

See all 23 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29430504

GET https://conductscience.org/api/papers/v1/29430504/references?page=2

API reference For AI assistants